131 related articles for article (PubMed ID: 33638886)
1. MiRNAs and radical prostatectomy: Current data, bioinformatic analysis and utility as predictors of tumour relapse.
Konoshenko MY; Laktionov PP
Andrology; 2021 Jul; 9(4):1092-1107. PubMed ID: 33638886
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
[TBL] [Abstract][Full Text] [Related]
3. Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?
Zhao Z; Stephan C; Weickmann S; Jung M; Kristiansen G; Jung K
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934131
[TBL] [Abstract][Full Text] [Related]
4. miRNAs and radiotherapy response in prostate cancer.
Konoshenko MY; Bryzgunova OE; Laktionov PP
Andrology; 2021 Mar; 9(2):529-545. PubMed ID: 33053272
[TBL] [Abstract][Full Text] [Related]
5. The miRNAs involved in prostate cancer chemotherapy response as chemoresistance and chemosensitivity predictors.
Konoshenko M; Laktionov P
Andrology; 2022 Jan; 10(1):51-71. PubMed ID: 34333834
[TBL] [Abstract][Full Text] [Related]
6. A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy.
Strand SH; Bavafaye-Haghighi E; Kristensen H; Rasmussen AK; Hoyer S; Borre M; Mouritzen P; Besenbacher S; Orntoft TF; Sorensen KD
Int J Cancer; 2019 Dec; 145(12):3445-3452. PubMed ID: 31125115
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations.
Zedan AH; Blavnsfeldt SG; Hansen TF; Nielsen BS; Marcussen N; Pleckaitis M; Osther PJS; Sørensen FB
PLoS One; 2017; 12(6):e0179113. PubMed ID: 28628624
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
9. Circulating microRNAs in plasma before and after radical prostatectomy.
McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
Yu L; Toriseva M; Tuomala M; Seikkula H; Elo T; Tuomela J; Kallajoki M; Mirtti T; Taimen P; Boström PJ; Alanen K; Nurmi M; Nees M; Härkönen P
Int J Cancer; 2016 Jul; 139(1):140-52. PubMed ID: 26891277
[TBL] [Abstract][Full Text] [Related]
11. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
[TBL] [Abstract][Full Text] [Related]
12. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression.
Fendler A; Jung M; Stephan C; Honey RJ; Stewart RJ; Pace KT; Erbersdobler A; Samaan S; Jung K; Yousef GM
Int J Oncol; 2011 Nov; 39(5):1183-92. PubMed ID: 21769427
[TBL] [Abstract][Full Text] [Related]
13. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
[TBL] [Abstract][Full Text] [Related]
14. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
Horning AM; Awe JA; Wang CM; Liu J; Lai Z; Wang VY; Jadhav RR; Louie AD; Lin CL; Kroczak T; Chen Y; Jin VX; Abboud-Werner SL; Leach RJ; Hernandez J; Thompson IM; Saranchuk J; Drachenberg D; Chen CL; Mai S; Huang TH
Prostate; 2015 Nov; 75(15):1790-801. PubMed ID: 26332453
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
[TBL] [Abstract][Full Text] [Related]
17. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
18. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
19. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].
Heidenreich A; Ohlmann C; Ozgür E; Engelmann U
Urologe A; 2006 Apr; 45(4):474-81. PubMed ID: 16465521
[TBL] [Abstract][Full Text] [Related]
20. A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy.
Li X; Huang H; Zhang J; Jiang F; Guo Y; Shi Y; Guo Z; Ao L
Prostate; 2020 Apr; 80(5):376-387. PubMed ID: 31961962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
